

Weekly diabetes drug provides similar benefits to daily version

January 17 2017



Credit: CC0 Public Domain

A weekly dipeptidyl peptidase-4 (DPP-4) inhibitor was just as effective at controlling type 2 diabetic patients' blood sugar as a daily DPP-4 inhibitor in a recent randomized clinical trial.

The drug, called omarigliptin, offers the prospect of a more convenient treatment for patients with diabetes.

"The observed glycaemic efficacy in the present study indirectly serves as further evidence of the feasibility of providing DPP-4 inhibition over the period of 1 week with a single once-weekly dose that is similar to that which can be achieved with daily administration," wrote the authors of the *Diabetes, Obesity and Metabolism* study.

More information: Ronald Goldenberg et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on m, *Diabetes, Obesity and Metabolism* (2017). [DOI: 10.1111/dom.12832](https://doi.org/10.1111/dom.12832)

Provided by Wiley

Citation: Weekly diabetes drug provides similar benefits to daily version (2017, January 17) retrieved 24 April 2024 from <https://medicalxpress.com/news/2017-01-weekly-diabetes-drug-similar-benefits.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--